FDA Expands Pembrolizumab-Enfortumab Vedotin Regimen in MIBC

FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer

July 10, 2026 The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-

FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with

<![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle Invasive Bladder Cancer]]>

<![CDATA[FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer]]>

Yüksel Ürün: EV+Pembrolizumab And GC+Durvalumab Reshape Perioperative MIBC Care

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared on X: “EV+pembrolizumab and GC+durvalumab reshape pe

Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II

Conditions : Esophageal Squamous Cell Carcinoma Interventions : Drug: Becotatug Vedotin; Drug: Tislelizumab; Drug: Lenvatinib Sponsors : Tia